# US 2001/0033842 A1 · Method of treating allergic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0033842 A1
- Document ID: US20010033842A1
- Status: Published application
- Kind: A1
- Application number: 09/802,077
- Filed: 2001-03-08
- Published: 2001-10-25
- Earliest claimed: 1991-08-14
- Assignees: Genentech, Inc.
- Inventors: Paula M. Jardieu; Leonard G. Presta
- Web page: https://patentgrep.com/patent/US20010033842A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/18: against material from animals or humans
- C07K 16/32: against translation products of oncogenes
- C07K 16/4291: {against IgE}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.

## Claims

### Claim 1

A polypeptide which is capable of binding to one of FCEL or FCEH but which is substantially incapable of binding to the other of FCEL or FCEH.

### Claim 2 (depends on 1)

The polypeptide of claim 1 which comprises amino acid sequence which is substantially homologous to an Fcε3-Fc68 4 sequence.

### Claim 3 (depends on 2)

The polypeptide of claim 2 which comprises amino acid sequence greater than about 80% homologous with an Fcε3-Fcε4 sequence and which contains at least about 50 residues.

### Claim 4 (depends on 1)

The polypeptide of claim 1 which is an immunoglobulin.

### Claim 5 (depends on 4)

The immunoglobulin of claim 4 which is capable of binding to FCEL but which is substantially incapable of binding to FCEH.

### Claim 6 (depends on 5)

The immunoglobulin of claim 5 which is an IgE analogue having a variant amino acid sequence within about residues 420 to 428, inclusive.

### Claim 7 (depends on 5)

The immunoglobulin of claim 5 which is an IgE analogue having a variant amino acid sequence within about residues 446 to 453, inclusive.

### Claim 8 (depends on 6)

The immunoglobulin of claim 6 further comprising IgE residues about from 373-390 and wherein the variant amino acid sequence is a deletion of one of residues 423-428.

### Claim 9 (depends on 4)

The immunoglobulin of claim 4 which further comprises a cytotoxic polypeptide, an enzyme, a diagnostic label, or an immunoglobulin variable domain capable of binding a predetermined antigen.

### Claim 10 (depends on 5)

The immunoglobulin of claim 5 which is an IgE analogue having a variant amino acid sequence within about residues 420-428, inclusive, and within about residues 446 to 453, inclusive.

### Claim 11 (depends on 10)

The imimunoglobulin of claim 10 which is capable of binding complement.

### Claim 12 (depends on 9)

The immunoglobulin of claim 9 wherein the antigen is CD8 or CD3.

### Claim 13 (depends on 9)

The immunoglobulin of claim 9 wherein the antigen is a lymphoid cell surface antigen.

### Claim 14 (depends on 9)

An immunoglobulin of claim 9 which comprises an IgG, IgA, IgD or IgM sequence.

### Claim 15

A method for treating an allergic disorder which comprises administering to a patient susceptible to an allergy a therapeutically effective amount of an FCEL or FCEH specific polypeptide, provided that the FCEH-specific polypeptide is incapable of crosslinking FCEH and inducing histamine release.

### Claim 16

A polypeptide capable of binding to FCEL and having a human IgE beta strand D sequence which is substantially incapable of binding to FCEH, said polypeptide containing no more than about 40 residues.

### Claim 17 (depends on 16)

The polypeptide of claim 16 having no more than about 30 residues.

### Claim 18 (depends on 17)

The polypeptide of claim 17 wherein a residue within the beta strand D domain has been deleted or substituted, or another residue inserted within the beta strand D domain.

### Claim 19

A polypeptide capable of binding to FCEH, containing a beta strand D sequence of IgE, and having no more than 19 residues.

### Claim 20 (depends on 1)

The polypeptide of claim 1 which is capable of binding to FCEH but not FCEL and comprises IgE sequence selected from about residues 420 to about 442.

### Claim 21 (depends on 19)

The polypeptide of claim 19 which comprises the IgE amino acid sequence of residues K423-R428.

### Claim 22 (depends on 1)

The polypeptide of claim 1 which comprises less than about 20 residues and which is conformationally constrained.

### Claim 23 (depends on 1)

The polypeptide of claim 1 which binds FCEL with at least about 75% of the affinity of native IgE and binds FCEH with no greater than about 10% of the affinity of native IgE.

### Claim 24 (depends on 4)

The immunoglobulin of claim 4 which comprises an IgE complementarity determining region.

### Claim 25 (depends on 4)

The immunoglobulin of claim 4 which is capable of binding to FCEH but which is substantially incapable of binding to FCEL.

### Claim 26 (depends on 25)

The immunoglobulin of claim 25 which is an IgE analogue having a variant amino acid sequence within about residues 373 to 390, inclusive or residues 446 to 453, inclusive.

### Claim 27 (depends on 25)

The immunoglobulin of claim 25 which is an IgE analogue having a variant amino acid sequence within about residues 382 to 390, inclusive or residues 446 to 453, inclusive.

### Claim 28 (depends on 27)

The immunoglobulin of claim 27 which further comprises a FCEH-binding loop EF and beta strand D domain.

### Claim 29 (depends on 24)

The immunoglobulin of claim 24 which further comprises an immunoglobulin variable domain capable of binding a predetermined antigen, an enzyme or a diagnostic label.

### Claim 30 (depends on 29)

The immunoglobulin of claim 29 wherein the antigen is CD8 or CD3.

### Claim 31 (depends on 29)

The immunoglobulin of claim 29 wherein the antigen is a lymphoid cell surface antigen.

### Claim 32 (depends on 25)

The immunoglobulin of claim 25 which comprises an IgG, IgA, IgD or IgM sequence.

### Claim 33 (depends on 25)

The immunoglobulin of claim 25 which binds FCEH with at least about 75% of the affinity of native IgE, and binds FCEL with no greater than about 10% of the efficiency of native IgE.

### Claim 34

A polypeptide capable of binding to FCEL and comprising a FCEL binding domain of the human loop AB-beta strand B of IgE, said polypeptide having no more than about 25 residues.

### Claim 35 (depends on 34)

The polypeptide of claim 34 which is human.

### Claim 36 (depends on 34)

The polypeptide of claim 34 having no more than about 10 residues.

### Claim 37 (depends on 34)

The polypeptide of claim 34 which is not A358-T389 or R383-I388.

### Claim 38 (depends on 34)

The polypeptide of claim 34 wherein beta strand D is deleted.

### Claim 39 (depends on 37)

The polypeptide of claim 37 wherein the amino acid sequence comprises the IgE sequence I382-T389.

### Claim 40

An antibody which is capable of binding to FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE, comprising a human Kabat CDR domain into which has been substituted an analogous residue from a Kabat CDR domain of MAE11, MAE13, MAE15, MAE17.

### Claim 41 (depends on 40)

The antibody of claim 40 wherein the residue is from the MAE11, MAE13 or MAE15 Kabat VH1 CDR domain.

### Claim 42 (depends on 40)

The antibody of claim 40 wherein the substituted amino acid sequence comprises from 1 to about 7 residues from a MAE11, MAE13 or MAE15 Kabat CDR domain

### Claim 43 (depends on 40)

The antibody of claim 40 wherein the substituted residue is from the MAE11, MAE13 or MAE15 Kabat VH1, VH2, VH3, VL1, VL2 and VL3 domains.

### Claim 44 (depends on 40)

The antibody of claim 40 which comprises non-CDR sequence from a Kabat human consensus antibody.

### Claim 45 (depends on 44)

The antibody of claim 44 wherein the consensus antibody is Kabat subgroup III for heavy chain and kappa subgroup I for light chain.

### Claim 46 (depends on 40)

The antibody of claim 40 further comprising a residue substituted from a MAE11, MAE13, MAE15 or MAE17 framework or VH-VL interface domain into the analogous residue of the human antibody.

### Claim 47 (depends on 40)

The antibody of claim 40 wherein the residue is from the heavy chain framework.

### Claim 48 (depends on 47)

The antibody of claim 47 wherein the residue is VH78, VH60 or VH61.

### Claim 49

An antibody which is capable of binding to FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE, comprising the heavy and light chain sequences of humae11ver.1, 2, 3, 4, 5, 6, 7, 7a, 8, 8a, 8b or 9.

### Claim 50 (depends on 48)

The antibody of claim 48 which is humae11ver.9.

### Claim 51

A bispecific antibody which is capable of binding to FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE.

### Claim 52

An antibody which is (a) monovalent for FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE and (b) is capable of an immunoglobulin effector function and comprises an Fc domain containing at least two heavy chains.

### Claim 53

An antibody which is capable of binding to FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE, comprising a human consensus heavy chain and light chain sequence.

### Claim 54 (depends on 52)

The antibody of claim 52 wherein the consensus heavy chain is Kabat subgroup III and the consensus light chain is Kabat kappa subgroup I.

### Claim 55

An antibody which is capable of binding to FCEL-bound IgE but is substantially incapable of binding to FCEH-bound IgE, comprising a human heavy chain and light chain sequence, and which has an IgE affinity which is substantially the same as or greater than that of MAE11 for IgE.

### Claim 56 (depends on 54)

The antibody of claim 54 wherein the affinity for IgE is about 0.1 to 100 times greater than that of MAE11 for IgE.

### Claim 57 (depends on 54)

The antibody of claim 54 wherein the human heavy chain or light chain sequence comprises a residue substituted from MAE11, MAE13 or MAE15.
